| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Sep 18, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 144,794 |
| Sep 18, 2023 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 317,842 |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | $0.38 | 20,000 |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 20,000 | $3.62 | -- |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | -- | 60,923 |
| Jun 06, 2019 |
Director
Trans History: 18
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
| Jun 06, 2019 |
Director
Trans History: 2
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
| Jun 06, 2019 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
| Jun 06, 2019 |
Director
Trans History: 14
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
| Jun 06, 2019 |
Director, Ten Percent Owner
Trans History: 14
|
Director, Ten Percent Owner | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,911 | -- | 21,911 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.